myriad_S_stacked.png
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
June 03, 2024 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official...
myriad_S_stacked.png
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
August 22, 2023 09:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Onsite Women’s Health, a leading national provider of...
myriad_S_stacked.png
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
July 24, 2023 08:00 ET | Myriad Genetics, Inc.
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is expected to identify more patients that could benefit...
Atossa Genetics Inc. Announces Pricing of a Public Offering of Common Stock and Warrants
January 24, 2014 08:30 ET | Atossa Genetics Inc.
SEATTLE, WA--(Marketwired - Jan 24, 2014) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has priced a public offering of approximately 5.8 million units at a price to the public of...
Atossa Genetics Inc. Announces Proposed Public Offering of Common Stock and Warrants
January 23, 2014 16:15 ET | Atossa Genetics Inc.
SEATTLE, WA--(Marketwired - Jan 23, 2014) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it intends to offer units consisting of shares of common stock and warrants in a public...
BREVAGen reclassified 64 percent of above average Gail risk subjects
CONTEMPORARY OBSTETRICS AND GYNECOLOGY OF DAYTON ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
September 30, 2013 10:34 ET | Genetic Technologies Group
DAYTON, Ohio, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Contemporary Obstetrics & Gynecology, part of the Providence Medical Group, today announced the availability of the BREVAGen™ predictive risk...
Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the Breast Cancer Symposium 2013
September 06, 2013 08:30 ET | Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Sep 6, 2013) -  Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, will display its ForeCYTE Breast Health Test at the 7th annual Breast Cancer...
Atossa Genetics to Announce Second Quarter 2013 Results on Wednesday, August 14, 2013
August 06, 2013 16:01 ET | Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Aug 6, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, today announced that it will issue financial results and corporate highlights for...
Atossa Genetics Added to Russell Microcap Index
July 15, 2013 08:30 ET | Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jul 15, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that the Company has been added to the Russell Microcap®...
Atossa Genetics to Present at Two Upcoming Investor Conferences
June 26, 2013 08:30 ET | Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jun 26, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company™, today announced that Kyle Guse, CFO and General Counsel, will be presenting at...